



Who we are

PREDI-LYNCH unites European cancer, clinical, biotechnology, data and patient expertise to transform prevention and early detection for people with Lynch syndrome.

What we are working on

We develop non-invasive liquid biopsy, biomarkers, multi-omics and AI approaches for earlier detection and personalised surveillance of Lynch syndrome-associated cancers.

What's the one thing we need next

We need collaboration to validate and integrate PREDI-LYNCH tools into healthcare, enabling earlier diagnosis, better risk assessment and personalised prevention.



**5 years Mission Cancer:
Stronger Through Connection**

BRUSSELS

29 SEPTEMBER – 01 OCTOBER



For more info visit:
www.predi-lynch.eu



EUROPEAN UNION

PREDI-LYNCH

Validated non-invasive liquid biopsy tests for cancer
PREDIction in LYNCH Syndrome.

